IDEAYA Biosciences $300M Public Offering
Analysis based on 9 articles · First reported Jun 08, 2026 · Last updated Jun 09, 2026
The public offering by IDEAYA Biosciences is expected to raise $300.0 million, providing capital for its operations and potentially impacting its stock price. The involvement of several major investment banks as book-running managers indicates significant market interest and support for the offering.
IDEAYA Biosciences, a precision medicine oncology company, announced and priced a public offering of common stock and pre-funded warrants, aiming to raise approximately $300.0 million. The offering includes 5,555,556 shares of common stock at $27.00 per share and pre-funded warrants for 5,555,576 shares at $26.9999 per warrant. IDEAYA Biosciences also granted the underwriters a 30-day option to purchase an additional 1,666,669 shares. JPMorgan Chase, Jefferies, Toronto-Dominion Bank — TD Cowen, UBS, and Cantor Fitzgerald are acting as joint book-running managers, with Wedbush Securities as lead manager. The offering is expected to close around June 10, 2026, subject to customary closing conditions. The proceeds will support IDEAYA Biosciences' ongoing discovery, development, and commercialization of cancer therapies.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard